On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments. Evergreen is a clinical-stage radiopharmaceutical company that offers Contract Development and Manufacturing (CDMO) services, drug discovery, and the commercialization of proprietary products. This transacti…

Benzinga

New York

United States

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio - Lantheus Holdings (NASDAQ:LNTH)

Ad Fontes Media

Media Bias/Fact Check

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal worth up to about $1 billion.

All Sides

The Business Journals

Advance Publications

Lantheus is on a buying spree. Its latest deal is worth up to $1B

Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds...

Globe Newswire

Apollo Global Management

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milest

Newswise

Charlottesville

Albemarle County

Virginia

cooley.com

Lantheus to Acquire Evergreen Theragnostics for up to $1 Billion // Cooley // Global Law Firm

In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and diagnostics company Evergreen Theragnostics, which could also receive up to $752.5 million in future milestone payments.

Endpoints News

Lantheus to buy radiopharma CDMO and diagnostic assets for $250M upfront

Lantheus Holdings Inc., a radiopharmaceutical healthcare company, announced Tuesday its plans to acquire Evergreen Theragnostics Inc. for up to $1 billion, marking a significant expansion of its capabilities in radiopharmaceutical development and manufacturing. The deal involves an upfront cash payment of $250 million and up to $752.5 million in milestone payments, according to a company Lantheus Holdings is acquiring Evergreen Theragnostics in a

USA Herald

Lantheus to Acquire Evergreen Theragnostics in $1B Deal - USA Herald

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

pharmaceutical-technology.com

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.The post Lantheus expands in neuro and oncology with LMI and Evergreen acquisitions appeared first on Medical Device Network.

Medical Device Network

Lantheus expands in neuro and oncology with LMI and Evergreen acquisitions

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio - Lantheus Holdings (NASDAQ:LNTH)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics